Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2000

View Archived Issues

Array BioPharma and Lilly form drug discovery collaboration

CollaGenex seeks FDA approval for new dosage form of Periostat

Karo Bio to acquire Novalon

Significant progress reported by Genzyme Molecular Oncology for 1999

Aventis launches Arava in Canada for treatment of rheumatoid arthritis

First phase II clinical trial of ABX-IL-8 begins in psoriasis

New phosphoglycolipid useful for protecting against cardiac ischemia-reperfusion damage

Chemokine receptor modulators in early development at AstraZeneca

Helsinn initiates phase III testing of in-licensed antiemetic

Carboxylic acid PPAR modulators presented by Ono

Merck's new GABA-A receptor modulators particularly useful for Alzheimer's disease

Scios compounds useful for conditions characterized by excess p38alpha or TGF-beta activity

Merck describes preparation and use of new anticoagulants

Uprima to be considered for ED next week by FDA advisory committee

Another indication for Enbrel will be discussed at advisory committee meeting

Novel tubulin-binding antimitotic agent characterized in vitro by Abbott scientists

Celgene's IMiDs and thalidomide show activity as COX-2 inhibitors

WP-769: a doxorubicin analogue that combines oral activity and enhanced effect against topo II

Promising flavonoid discovered by Dutch investigators for preventing doxorubicin cardiotoxicity

Ro-31-7453: extensive preclinical and early clinical data presented this week to the AACR

DuPont licenses two cardiac compounds from Adenosine Therapeutics

Clinical study suggests SuperGen's Nipent effective in treating GVHD

FDA gives go-ahead for Access to commence OraDisc clinical trials

Matrix files initial section of IntraDose NDA with FDA

German researchers provide data supporting therapy with S-4718 + ciclosporin in cardiac transplants

Efficacy and mechanism of action of FR-167653 in protecting against lung I/R injury

Newly formed company to market TOBI in the Dutch market

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026